Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Neurogene (NGNE) Stock Price & Analysis
417 Followers
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.20 - $53.00
Previous Close$41.62
Volume124.44K
Average Volume (3M)139.59K
Market Cap
$534.94M
Enterprise Value$463.92M
Total Cash (Recent Filing)$82.06M
Total Debt (Recent Filing)$11.04M
Price to Earnings (P/E)-21.8
Beta0.97
Next Earnings
May 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding12,852,985
10 Day Avg. Volume208,218
30 Day Avg. Volume139,585
Standard Deviation0.29
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.03
Forecast
1Y Price Target
$49.50Price Target Upside18.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Neurogene News
PremiumCompany Announcements
Neurogene Updates CSO Stuart Cobb’s Compensation Agreement
PremiumCompany Announcements
Neurogene Inc. Files SEC Form 8-K Report
PremiumCompany Announcements
Neurogene Reports Positive Results in Rett Syndrome Trial
PremiumCompany Announcements
Neurogene Enhances Executive Compensation and Severance Terms
PremiumCompany Announcements
Neurogene Inc. Files Key SEC Report
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.20 and its highest was $53.00 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is May 08, 2024 which is in 3 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Mar 18, 2024. The company reported $2.93 earnings per share for the quarter, beating the consensus estimate of -$1.173 by $4.103.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurogene have?
Neurogene has 12,852,985 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of $2.93 in its last earnings report, beating expectations of -$1.173. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 9M.
---
Neurogene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (18.93% Upside)
$49.50 (18.93% Upside)
Hedge Fund Trend
Increased
By 148.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
197.28%
12-Months-Change
Fundamentals
Return on Equity
-25.91%
Trailing 12-Months
Asset Growth
91.96%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Months Forecast
Average Price Target
$49.50
▲(18.93% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Editas Medicine
―
Ionis Pharmaceuticals
―
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+22.36%
reiterated a buy rating 2 months ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +22.36% per trade.
---